Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes
Topics: Pregnancy, Accuracy, Safety
Research Spotlight: “Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes” Polsky S, et al. Diabetes Technol Ther. 2024;26(5):307-12.
Background: Diabetes during pregnancy is associated with increased risks for both maternal and fetal complications. Continuous glucose monitoring (CGM) systems, such as the Dexcom G7, can help manage glucose levels more effectively. This study evaluates the accuracy and safety of the Dexcom G7 CGM system in pregnant women with type 1 diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes mellitus (GDM).
Key question: How accurate and safe is the Dexcom G7 CGM system for use in pregnant women with diabetes?
Main outcomes of the study:
- Accuracy:
- Primary Endpoint: 83.2% of CGM values in the 70-180 mg/dL range were within 15% of comparator values.
- Secondary Endpoint: 92.5% of CGM values in the 40-400 mg/dL range met the %20/20 agreement rate.
- Mean Absolute Relative Difference (MARD): Overall MARD was 9.5%.
- Consensus Error Grid Analysis: 99.8% of paired values were in clinically acceptable zones A and B.
- Safety: No serious adverse events were reported. The 10-day sensor survival rate was 90.3%.
- Additional Findings: Accuracy was consistent across different types of diabetes, gestational ages, HbA1c levels, and BMI categories. The overall percentage of CGM readings in the pregnancy-specific time-in-range of 63-140 mg/dL was 71.8%.
Key takeaways for healthcare providers:
- The Dexcom G7 CGM system is accurate and safe for use in pregnant women with diabetes, providing reliable glucose readings without the need for confirmatory fingerstick testing.
- CGM can help users maintain tight glycemic control during pregnancy, potentially reducing the risk of adverse maternal and neonatal outcomes.
- The G7 system’s ease of use and high accuracy make it a valuable tool for managing diabetes in pregnancy.
Related Content
Title: Long-Term Improvements in Glycemic Control with Dexcom CGM Use in Adults with Noninsulin-Treated Type 2 Diabetes Topics: Long-Term Outcomes, Type 2 Diabetes, Noninsulin-Treated Research...
Topic: Type 2 Diabetes, Newly Diagnosed, Early Initiation Key question: Does the glycemic legacy effect begin as early as the 1st year in real-world populations? Research Spotlight: “The Legacy Effect...